ND081

ND081 is a potential first-in-class multi-specific antibody developed for the treatment of inflammatory bowel disease (IBD). It is designed to address multiple inflammation-related pathways, offering a novel approach for patients with IBD and potentially other inflammatory conditions. The drug leverages Numab Therapeutics' proprietary antibody engineering platforms, aiming to overcome historical drug discovery barriers in immunology. As of late 2024, ND081 is in preclinical development with plans for clinical proof-of-concept studies. Kaken Pharmaceutical has obtained an option to license and commercialize the drug in certain Asian territories, supporting global development up to Phase 2a[1][6][7].